CLIFF Stock Chart & Stats
$0.07
$0.00(0.00%)
At close: 4:00 PM EST
$0.07
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.07 - $0.17
Previous CloseN/A
Volume25.00
Average Volume (3M)100.00
Market Cap
$30.62M
Enterprise Value$22.62M
Total Cash (Recent Filing)$45.33M
Total Debt (Recent Filing)$4.39M
Price to Earnings (P/E)―
Beta-0.07
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding267,525,360
10 Day Avg. Volume0
30 Day Avg. Volume100
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.32
Price to Sales (P/S)0.86
P/FCF Ratio-45.71
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue0.62
Enterprise Value/Gross Profit1.10
Enterprise Value/Ebitda-2.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage (debt-to-equity ~0.04) gives durable financial flexibility, allowing the company to absorb near-term losses, fund restructuring or targeted investments without immediate refinancing pressure. That cushion supports operational continuity across 2–6 months while turnaround actions are implemented.
High Gross MarginsA ~56.7% gross margin indicates the core cell-processing and storage service retains significant pricing spread over direct costs. Persistently high gross margin provides structural room to restore profitability if operating expenses are controlled or scaled, making margin recovery a realistic path over several quarters.
Recurring Revenue ModelRevenue primarily from upfront enrolment and ongoing storage fees creates predictable, annuity-like cashflows and strong customer lifetime value. Distribution via hospitals and clinics embeds sales channels, supporting steady new enrolments and durable demand absent major regulatory shifts over the medium term.
Bears Say
Deep Operating LossesSustained negative EBIT (~-37%) and net margins (~-32%) show the company is burning operating profit at scale. Such large structural losses require substantive cost reduction or material revenue expansion to correct, and they meaningfully weaken the firm's ability to reinvest and achieve durable profitability within several quarters.
Negative Cash GenerationOngoing negative operating and free cash flow constrains internal funding for operations and growth, increasing reliance on external capital if losses persist. Even with recent improvement versus prior year, lack of consistent cash generation raises execution and liquidity risk over the next few quarters.
Negative Returns On CapitalA negative ROE (~-5.7%) indicates the company’s equity base is not producing returns, reflecting a deterioration from earlier profitable periods. Persistently negative returns can deter investors and limit the firm's ability to raise equity on favorable terms, hampering strategic flexibility over the medium term.
Cordlife Group News
CLIFF FAQ
What was Cordlife Group Limited’s price range in the past 12 months?
Cordlife Group Limited lowest stock price was $0.07 and its highest was $0.17 in the past 12 months.
What is Cordlife Group Limited’s market cap?
Cordlife Group Limited’s market cap is $30.62M.
When is Cordlife Group Limited’s upcoming earnings report date?
Cordlife Group Limited’s upcoming earnings report date is Aug 07, 2026 which is in 32 days.
How were Cordlife Group Limited’s earnings last quarter?
Cordlife Group Limited released its earnings results on May 13, 2026. The company reported -$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.005.
Is Cordlife Group Limited overvalued?
According to Wall Street analysts Cordlife Group Limited’s price is currently Overvalued.
Does Cordlife Group Limited pay dividends?
Cordlife Group Limited pays a Annually dividend of $0.006 which represents an annual dividend yield of N/A. See more information on Cordlife Group Limited dividends here
What is Cordlife Group Limited’s EPS estimate?
Cordlife Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cordlife Group Limited have?
Cordlife Group Limited has 267,525,360 shares outstanding.
What happened to Cordlife Group Limited’s price movement after its last earnings report?
Cordlife Group Limited reported an EPS of -$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cordlife Group Limited?
Currently, no hedge funds are holding shares in CLIFF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cordlife Group Limited
Established in Singapore in 2001, Cordlife Group Limited functions as an investment holding company, delivering cord blood banking solutions across a global footprint that includes Singapore, Hong Kong, India, Malaysia, and the Philippines. Its operations are structured into two distinct divisions: Banking and Diagnostics. The Banking division is responsible for the collection, processing, storage, and analysis of vital biological samples such as cord blood, cord lining, and various tissue samples. Meanwhile, the Diagnostics division furnishes an array of diagnostic tests, encompassing genetic and metabolic screenings for newborns, pediatric vision and hearing assessments, allergen testing for children, and genetic evaluations for talent identification. Beyond these core services, Cordlife also engages in corneal lenticule banking, gut microbiome storage, and offers lifestyle-focused genetic screening for adults. The company further provides "Moms Up," a mobile application designed to supply parenting information and resources pertinent to health, wellness, and lifestyle needs. Completing its diverse portfolio, Cordlife offers medical laboratory services, marketing support, property investment, alongside specialized consulting and research and development in the medical and pharmaceutical sectors.
Technical Analysis
Raffles Medical Group
―
Thomson Medical Group Ltd.
―
ISEC Healthcare Ltd
―
OUE Lippo Healthcare Limited
―
Bangkok Dusit Medical Services Public Co Ltd Shs UnSp Singapore Depositary Receipt Repr 2/1 Sh
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.12% Other Institutional Investors
99.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---